A Study of MK-2214 in Adults With Mild Cognitive Impairment or Mild-to-Moderate Alzheimer's Disease (MK-2214-002)
NCT05466422
·
clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
34
Enrollment
INDUSTRY
Sponsor class
Conditions
Alzheimer Disease
Interventions
BIOLOGICAL:
MK-2214
DRUG:
Placebo
Sponsor
Merck Sharp & Dohme LLC